EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches

Omima S Mohammed, Hany G Attia, Bassim M S A Mohamed, Marawan A Elbaset, Hany M Fayed

Journal of Pharmacy & Pharmaceutical Sciences · 07.11.2023 · 26

DOI: 10.3389/jpps.2023.11808 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Pharmacy & Pharmaceutical Sciences, online erschienen am 07.11.2023. Verfasst von Omima S Mohammed und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, College of Medicine, Najran University, Najran, Saudi Arabia. Hauptthemen laut MEDLINE: Drug Repositioning, Liver Cirrhosis. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 155 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Long-term liver injuries lead to hepatic fibrosis, often progressing into cirrhosis, liver failure, portal hypertension, and hepatocellular carcinoma. There is currently no effective therapy available for liver fibrosis. Thus, continuous investigations for anti-fibrotic therapy are ongoing. The main theme of anti-fibrotic investigation during recent years is the rationale-based selection of treatment molecules according to the current understanding of the pathology of the disease. The research efforts are mainly toward repurposing current FDA-approved drugs targeting etiological molecular factors involved in developing liver fibrosis. In parallel, investigations also focus on experimental small molecules with evidence to hinder or reverse the fibrosis. Natural compounds, immunological, and genetic approaches have shown significant encouraging effects. This review summarizes the efficacy and safety of current under-investigation antifibrosis medications targeting various molecular targets, as well as the properties of antifibrosis medications, mainly in phase II and III clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug RepositioningLiver CirrhosisHumansLiver

Stichwörter der Autor:innen

HSCsanti-fibrotic agentsliver fibrosispharmacotherapytherapeutic targets

Autor:innen und Institutionen

  • Department of Microbiology, College of Medicine, Najran University, Najran, Saudi Arabia.
  • Department of Pharmacognosy, College of Pharmacy, Najran University, Najran, Saudi Arabia.
  • Department of Pharmacology, Medical Research and Clinical Studies Institute, National Research Centre, Cairo, Egypt.

Zitieren

APA

Mohammed, O. S., Attia, H. G., Mohamed, B. M. S. A., Elbaset, M. A., & Fayed, H. M. (2023). Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches. Journal of Pharmacy & Pharmaceutical Sciences, 26. https://doi.org/10.3389/jpps.2023.11808

Vancouver

Mohammed OS, Attia HG, Mohamed BMSA, Elbaset MA, Fayed HM. Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches. Journal of Pharmacy & Pharmaceutical Sciences. 2023;26. doi:10.3389/jpps.2023.11808

BibTeX
@article{Mohammed2023,
  author = {Mohammed, Omima S and Attia, Hany G and Mohamed, Bassim M S A and Elbaset, Marawan A and Fayed, Hany M},
  title = {Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches},
  journal = {Journal of Pharmacy & Pharmaceutical Sciences},
  year = {2023},
  volume = {26},
  doi = {10.3389/jpps.2023.11808}
}
Kostenlos starten →